The therapeutic monoclonal antibody market
Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety...
Gespeichert in:
| Veröffentlicht in: | mAbs 2015-01, Vol.7 (1), p.9-14 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 1 |
| container_start_page | 9 |
| container_title | mAbs |
| container_volume | 7 |
| creator | Ecker, Dawn M Jones, Susan Dana Levine, Howard L |
| description | Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion. |
| doi_str_mv | 10.4161/19420862.2015.989042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4161_19420862_2015_989042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652378979</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-407c7dc67f03282bb02488369f4e2ac5402630aedb2ebbb007e28d2b18b863023</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobsz9A5FditCZnKb5uFFk-AUDb-Z1SNPUVdtmJq2yf29Lt6E3npsc8r7nPYcHoXOC55Qwck0kBSwYzAGTZC6FxBSO0Lj_jrDg-PjQMxihaQjvuC-OCcenaARJAlJKNkZXq7WdNWvr9ca2TWFmlaudKV2ty5mumyJ12XZWaf9hmzN0kusy2OnunaDXh_vV4ilavjw-L-6WkaEkbiKKueGZYTzHMQhIUwxUiJjJnFrQJqEYWIy1zVKwaadibkFkkBKRik6AeIJuhtxNm1Y2M7ZuvC7VxhfdHVvldKH-KnWxVm_uS1EGkEjZBVzuArz7bG1oVFUEY8tS19a1QRGWQMyF5L2VDlbjXQje5oc1BKuetNqTVj1pNZDuxi5-n3gY2nPtDLeDoahz5yv97XyZqUZvS-dzr2tTBBX_u-IHCX2Mjw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652378979</pqid></control><display><type>article</type><title>The therapeutic monoclonal antibody market</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Ecker, Dawn M ; Jones, Susan Dana ; Levine, Howard L</creator><creatorcontrib>Ecker, Dawn M ; Jones, Susan Dana ; Levine, Howard L</creatorcontrib><description>Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.</description><identifier>ISSN: 1942-0862</identifier><identifier>EISSN: 1942-0870</identifier><identifier>DOI: 10.4161/19420862.2015.989042</identifier><identifier>PMID: 25529996</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Antibodies, Monoclonal - economics ; Antibodies, Monoclonal - therapeutic use ; Drug Approval ; Europe ; Humans ; Marketing ; Reviews ; United States</subject><ispartof>mAbs, 2015-01, Vol.7 (1), p.9-14</ispartof><rights>2015 BioProcess Technology Consultants, Inc. 2015</rights><rights>2015 BioProcess Technology Consultants, Inc. 2015 BioProcess Technology Consultants, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c413t-407c7dc67f03282bb02488369f4e2ac5402630aedb2ebbb007e28d2b18b863023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622599/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622599/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25529996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ecker, Dawn M</creatorcontrib><creatorcontrib>Jones, Susan Dana</creatorcontrib><creatorcontrib>Levine, Howard L</creatorcontrib><title>The therapeutic monoclonal antibody market</title><title>mAbs</title><addtitle>MAbs</addtitle><description>Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.</description><subject>Antibodies, Monoclonal - economics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Drug Approval</subject><subject>Europe</subject><subject>Humans</subject><subject>Marketing</subject><subject>Reviews</subject><subject>United States</subject><issn>1942-0862</issn><issn>1942-0870</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1LwzAUhoMobsz9A5FditCZnKb5uFFk-AUDb-Z1SNPUVdtmJq2yf29Lt6E3npsc8r7nPYcHoXOC55Qwck0kBSwYzAGTZC6FxBSO0Lj_jrDg-PjQMxihaQjvuC-OCcenaARJAlJKNkZXq7WdNWvr9ca2TWFmlaudKV2ty5mumyJ12XZWaf9hmzN0kusy2OnunaDXh_vV4ilavjw-L-6WkaEkbiKKueGZYTzHMQhIUwxUiJjJnFrQJqEYWIy1zVKwaadibkFkkBKRik6AeIJuhtxNm1Y2M7ZuvC7VxhfdHVvldKH-KnWxVm_uS1EGkEjZBVzuArz7bG1oVFUEY8tS19a1QRGWQMyF5L2VDlbjXQje5oc1BKuetNqTVj1pNZDuxi5-n3gY2nPtDLeDoahz5yv97XyZqUZvS-dzr2tTBBX_u-IHCX2Mjw</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Ecker, Dawn M</creator><creator>Jones, Susan Dana</creator><creator>Levine, Howard L</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>The therapeutic monoclonal antibody market</title><author>Ecker, Dawn M ; Jones, Susan Dana ; Levine, Howard L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-407c7dc67f03282bb02488369f4e2ac5402630aedb2ebbb007e28d2b18b863023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antibodies, Monoclonal - economics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Drug Approval</topic><topic>Europe</topic><topic>Humans</topic><topic>Marketing</topic><topic>Reviews</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ecker, Dawn M</creatorcontrib><creatorcontrib>Jones, Susan Dana</creatorcontrib><creatorcontrib>Levine, Howard L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>mAbs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ecker, Dawn M</au><au>Jones, Susan Dana</au><au>Levine, Howard L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The therapeutic monoclonal antibody market</atitle><jtitle>mAbs</jtitle><addtitle>MAbs</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>7</volume><issue>1</issue><spage>9</spage><epage>14</epage><pages>9-14</pages><issn>1942-0862</issn><eissn>1942-0870</eissn><abstract>Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>25529996</pmid><doi>10.4161/19420862.2015.989042</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1942-0862 |
| ispartof | mAbs, 2015-01, Vol.7 (1), p.9-14 |
| issn | 1942-0862 1942-0870 |
| language | eng |
| recordid | cdi_crossref_primary_10_4161_19420862_2015_989042 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Drug Approval Europe Humans Marketing Reviews United States |
| title | The therapeutic monoclonal antibody market |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T04%3A56%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20therapeutic%20monoclonal%20antibody%20market&rft.jtitle=mAbs&rft.au=Ecker,%20Dawn%20M&rft.date=2015-01-01&rft.volume=7&rft.issue=1&rft.spage=9&rft.epage=14&rft.pages=9-14&rft.issn=1942-0862&rft.eissn=1942-0870&rft_id=info:doi/10.4161/19420862.2015.989042&rft_dat=%3Cproquest_cross%3E1652378979%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652378979&rft_id=info:pmid/25529996&rfr_iscdi=true |